簡易檢索 / 詳目顯示
| 研究生： |
林時羽 Lin , Shyr-Yeu |
|---|---|
| 論文名稱： |
生技新創募資企劃案 A Biotech Company Fundraising Proposal |
| 指導教授： |
黃國峯
Huang, Kuo-Feng |
| 口試委員: |
林谷合
Lin, Ku-Ho 酈芃羽 Li, Peng-Yu |
| 學位類別： |
碩士
Master |
| 系所名稱： |
商學院 - 經營管理碩士學程(EMBA) Executive Master of Business Administration(EMBA) |
| 論文出版年： | 2026 |
| 畢業學年度： | 114 |
| 語文別： | 英文 |
| 論文頁數： | 125 |
| 中文關鍵詞： | 再生醫學 、精準醫療 、基因體學 、幹細胞醫學 、組織工程 、奈米醫學 、人工智慧 、資本效率 、多元化布局 、風險控管 |
| 外文關鍵詞： | Regenerative medicine, Precision medicine, Genomics, Stem cell medicine, Tissue engineering, Nanomedicine, Artificial intelligence, Capital efficiency, Diversification, Risk mitigation |
| 相關次數： | 點閱：16 下載：0 |
| 分享至: |
| 查詢本校圖書館目錄 查詢臺灣博碩士論文知識加值系統 勘誤回報 |
GenoRenew Therapeutics 是一家先進的生物科技公司，專注於再生醫學與精準醫療，其使命在於永久性治癒退化性與慢性疾病，而非僅止於症狀管理。透過整合基因體學、幹細胞醫學、組織工程、奈米醫學與人工智慧，公司打造了一個強大的多平台生態系統，旨在修復生物功能並延長人類的健康壽命。
在科學與研發層面，GenoRenew 採取平台型研發模式，而非依賴單一藥物候選項目。此一策略使公司能夠同步開發多項高影響力療法，鎖定神經退化性疾病、代謝性疾病等重大且尚未被充分滿足的醫療需求。透過 AI 驅動的基因體分析、智慧型生物材料、幹細胞治療以及精準藥物傳輸系統，公司得以提供高度個人化、具再生潛力的治療方案，同時降低研發風險並縮短開發時程。
在組織與公司治理層面，GenoRenew 由一支跨領域領導團隊所帶領，結合深厚的臨床專業、世界級的科學領導力，以及經驗豐富的營運管理能力。此一組織架構確保突破性科研成果能有效轉化為具規模性、符合法規且具商業可行性的療法，並在高度協作、科學嚴謹與長期價值創造的企業文化支持下穩健推進。
GenoRenew 的商業模式強調資本效率、多元化布局與風險控管。其收入來源採取分階段策略，初期以研究工具、技術授權與製造服務為主，並逐步轉向高價值治療產品的全球商業化。透過跨專案共享基礎設施，公司在維持穩健且多元研發管線的同時，實現高度的成本效率。
在財務策略方面，公司採取紀律化、以里程碑為導向的資本配置模式，結合創投資金、策略合作夥伴、非稀釋性補助以及授權收入，以延長營運資金週期並降低股權稀釋風險。透過明確的價值關鍵節點——如臨床驗證與法規核准——公司致力於驅動顯著的企業估值成長。
總體而言，GenoRenew Therapeutics 將自身定位為一家具備高度擴展性的再生醫學產業領導者，在實現人道醫療使命的同時，創造具吸引力的經濟回報。公司為投資人提供多元退出機制，包括首次公開募股（IPO）、併購，以及策略性授權，並致力於為全球高齡化社會重新定義未來醫療的樣貌。
GenoRenew Therapeutics is an advanced biotechnology company focused on regenerative and precision medicine, with the mission of permanently curing degenerative and chronic diseases rather than managing symptoms. By integrating genomics, stem cell medicine, tissue engineering, nanomedicine, and artificial intelligence, the company has built a powerful, multi-platform ecosystem designed to restore biological function and extend healthy human longevity.
Scientifically, GenoRenew adopts a platform-based development model rather than relying on a single drug candidate. This approach enables the simultaneous development of multiple high-impact therapies targeting major unmet medical needs such as neurodegenerative and metabolic diseases. AI-driven genomic analysis, intelligent biomaterials, stem cell therapy and targeted drug-delivery systems allow for highly personalized, regenerative treatments while reducing development risk and timelines.
From an organizational and governance perspective, the company is led by a multidisciplinary leadership team combining deep clinical expertise, world-class scientific leadership, and experienced operational management. This structure ensures that breakthrough discoveries are translated into scalable, regulatory-compliant, and commercially viable therapies, supported by a strong culture of collaboration, scientific rigor, and long-term value creation.
GenoRenew’s business model emphasizes capital efficiency, diversification, and risk mitigation. Revenue generation follows a phased strategy, beginning with research tools, licensing, and manufacturing services, and transitioning toward global commercialization of high-value therapeutic products. Shared infrastructure across programs enables cost efficiency while maintaining a robust and diversified pipeline.
Financially, the company employs a disciplined, milestone-driven capital strategy, leveraging venture capital, strategic partnerships, non-dilutive grants, and licensing revenues to extend runway while minimizing shareholder dilution. Clear value inflection points—such as clinical validation and regulatory approvals—are designed to drive significant valuation growth.
Ultimately, GenoRenew Therapeutics positions itself as a scalable regenerative-medicine powerhouse, aligning humanitarian medical impact with strong economic returns. The company offers investors multiple exit pathways, including IPOs, mergers and acquisitions, and strategic licensing, while aiming to redefine the future of healthcare for aging populations worldwide.
Acknowledgements i
中文摘要 ii
Abstract iv
Table of contents vi
Introduction:
Chapter 1 GenoRenew Therapeutics 1
1.1 Introducing GenoRenew Therapeutics: Pioneering the Future of Biotechnology 2
1.2 Our Vision: Transforming Healthcare Through Innovation 3
1.3 The Biotech Challenge & Our Opportunity 3
1.3.1 Navigating Complexity with Clarity: The Biotech Landscape 3
1.3.2 Market Trends and Investment Landscape 5
Biotechnology Platform:
Chapter 2 Novel Techniques Powering Our Platform 7
2.1 Convergence of Revolutionary Technologies: A New Era of Therapeutic Innovation 8
2.1.1 Cell therapy with stem cell medicine 9
2.1.2 Tissue engineering, biomaterial and nanomedicine 17
2.1.3 Genomics platform 25
Chapter 3 Real-World Impact: Targeting Critical Unmet Medical Needs 34
3.1 Tackling Diseases with No Curative Options 35
3.2 Delivering Superior Solutions Where Current Therapies Fall Short 36
3.3 Transforming the Patient Experience and Healthcare Outcomes 38
3.4 A Pipeline Designed for Maximum Clinical and Commercial Impact 39
3.5 The Power of Our Integrated Platform: From Discovery to Real-World Application 40
3.6 Why This Matters Profoundly for Investors 41
3.7 In Summary 42
Chapter 4 Competitive Analysis and Key Differentiators: How We Lead in a Rapidly Evolving Biotech Landscape 43
4.1 The Competitive Landscape: Where We Stand 44
4.2 Our Key Differentiators: Why We Win 47
4.3 A Durable and Defensible Competitive Position 51
4.4 Conclusion 52
Leadership Team:
Chapter 5 Leadership & Team: Bridging Science and Business 54
5.1 Visionary CEO Leadership 55
5.2 World-Class Scientific Officers 56
5.3 Experienced Operational Leaders 57
5.4 Building a Culture of Innovation and Excellence 59
From Funding to Profitability:
Chapter 6 Strategic Partnerships & Funding Vision: Fueling Innovation, Accelerating Growth, and Maximizing Value 64
6.1 Building High-Value Strategic Partnerships That Accelerate Development and Mitigate Risk 65
6.2 A Funding Vision Designed for Capital Efficiency and Long-Term Value Creation 67
6.3 The Value of Our Integrated Partnership & Funding Strategy for Investors 70
6.4 Conclusion 71
Chapter 7 Business Model and Revenue Strategy: A Scalable Path Toward Transformative Growth and Sustainable Value Creation 72
7.1 A Platform-Based Business Model: Multiplying Value Across Indications and 74
7.2 Diversified Revenue Strategy: Multi-Stage Value Capture 76
7.3 Market Access Strategy: Paving the Way for Long-Term Commercial Success 79
7.4 De-Risking Revenue Through Smart Portfolio Design 80
7.5 Strong Unit Economics and Scalable Cost Structure: Foundations of Profitability 81
7.6 Creating Lasting Investor Value: Our Commitment 82
7.7 Conclusion 82
Chapter 8 Funding Plan and Allocation of Funds: A Disciplined Strategy for Accelerated Growth and Exceptional Long-Term Value Creation 84
8.1 Funding Strategy Overview: A De-Risked Pathway to Market Leadership and Superior Returns 86
8.2 Allocation of Funds Across Strategic Priorities: Precision Deployment for Maximum Impact and Accelerated ROI 89
8.3 Milestones and Value Inflection Points: Driving Valuation Growth and Investor Confidence 93
8.4 Why Our Funding Plan Creates Lasting Value for Investors: A Blueprint for Superior Returns 95
8.5 Conclusion 97
Chapter 9 Financial Projections: A Clear Path Toward Exponential Revenue Growth, Strategic Value Inflection, and Sustainable Long-Term Profitability 98
9.1 Revenue Growth Timeline: Strategic Inflection Points for Accelerated Value Capture 99
9.2 Expense Structure and Disciplined Cost Management: Fueling Growth with Capital Efficiency 102
9.3 Profitability Outlook: A Clear Trajectory to Robust Financial Health 104
9.4 Long-Term Value Creation for Investors: A Multi-faceted Approach to Superior Returns 106
9.5 Conclusion 107
Chapter 10 Exit Strategy: Maximizing Investor Returns Through Strategic Positioning and Long-Term Value Creation 109
10.1 A Multi-Path Exit Strategy Designed for Maximum Optionality 110
10.2 Key Value Inflection Points That Drive Exit Readiness 113
10.3 Why Our Exit Strategy Maximizes Investor Value 114
10.4 Conclusion 114
Conclusion:
Chapter 11 Conclusion: Invest in GenoRenew – Where Transformative Science Meets Unparalleled Investor Value 116
References:
References 120
Aatif M, AboHoussien MS, Elhendawy AT, Muteeb G, Fabella EL, and Khafaga DSR. Nanomedicine for prostate cancer: Modern therapies based on green synthesis of nanoparticles. SLAS Technol 2025: 35; 100362.
Abdi SMY, Al-Bakri SSM, and Nordin N. Insights on the Characteristics and Therapeutic Potential of Mesenchymal Stem Cell-derived Exosomes for Mitigation of Alzheimer's Disease's Pathogenicity: A Systematic Review. Cell Biochem Biophys 2025: 83; 1399-1414.
Abedi N, Sadeghian A, Kouhi M, Haugen HJ, Savabi O, and Nejatidanesh F. Immunomodulation in Bone Tissue Engineering: Recent Advancements in Scaffold Design and Biological Modifications for Enhanced Regeneration. ACS Biomater Sci Eng 2025: 11; 1269-1290.
AbuOwida H, Ibrahim Mohammad S, and Vasudevan A. Next-generation nanomedicine: the impact of graphene oxide and quantum dots on drug delivery. J Biomater Sci Polym Ed 2025; 1-19.
Advani D, Farid N, Tariq MH, and Kohli N. A systematic review of mesenchymal stem cell secretome: Functional annotations, gene clusters and proteomics analyses for bone formation. Bone 2025: 190; 117269.
Aggarwal P, Oza RR, Solanki H, Charan J, Kaur RJ, Deora S, Saini L, Kumar D, Choudhary R, Bhardwaj P, et al. Efficacy & safety of stem cell therapy for treatment of acute myocardial infarction: A systematic review & meta-analysis. Indian J Med Res 2025: 161; 647-664.
Ahmad Q, Mehdi S, Mehmood MH, Asif MT, and Ali MM. Stem cell therapy: a promising frontier in modern medicine with a comprehensive overview of their biology and potential therapeutic applications in chronic non-healing cutaneous injuries. Inflammopharmacology 2025: 33; 5639-5666.
Ajekiigbe VO, Agbo CE, Ogieuhi IJ, Anthony CS, Adewole OA, Ahmed B, Akingbola A, Nwankwo CK, Kayode AT, Chima UE, et al. Innovative approaches to treatment of eye diseases: advances in stem cell therapy use in ophthalmology. Int Ophthalmol 2025: 45; 113.
Akbaba H, Homer L, Tran TBT, Bhaskar N, Sharma N, Erel-Akbaba G, Pahal S, and Nguyen TD. Gene therapy strategies in tissue engineering: advances and applications for regenerative therapy. Trends Biotechnol 2025.
Akhtar S and Zuhair F. Advancing Nanomedicine Through Electron Microscopy: Insights Into Nanoparticle Cellular Interactions and Biomedical Applications. Int J Nanomedicine 2025: 20; 2847-2878.
Al Amin M, Zehravi M, Sweilam SH, Shanmugarajan TS, Arjun U, Nagaiyan MB, Reddy SM, Subash V, Swarnalatha KM, Pazhanikumar A, et al. Clinical insights into catechin-based nanomedicine: a review of therapeutic potential in neurodegenerative diseases. 3 Biotech 2025: 15; 294.
Al Khafaji AT, Barakat AM, Jooda Al Zaidy A, Taan AA, and Al-Aouadi RFA. Recent Advances in Cardiac Tissue Engineering: Innovations and Future Directions. Biotechnol J 2025: 20; e70116.
Ali SA, Mahmood Z, Mubarak Z, Asad M, Sarfraz Chaudhri MT, Bilal L, Ashraf T, Khalifa TN, Ashraf T, Saleem F, et al. Assessing the Potential Benefits of Stem Cell Therapy in Cardiac Regeneration for Patients With Ischemic Heart Disease. Cureus 2025: 17; e76770.
Amin MN, Hashish R, Agha Tabari K, Swami SS, Kasagga A, Assefa AK, and Yu AK. Immunomodulatory Role of Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review. Cureus 2025: 17; e86988.
Amirhossein H, Arash A, Aida N, Asadollah A, and Hussein AG. Immunomodulatory Functions of Mesenchymal Stem Cells in Tissue Engineering. Arch Razi Inst 2025: 80; 313-324.
Ao R, Liang W, Wang Z, Li Q, Pan X, Zhen Y, and An Y. Delivery Strategies of Growth Factors in Cartilage Tissue Engineering. Tissue Eng Part B Rev 2025: 31; 374-389.
Babighian S, Zanella MS, Gattazzo I, Galan A, Gagliano C, D'Esposito F, and Zeppieri M. Atrophic Macular Degeneration and Stem Cell Therapy: A Clinical Review. Adv Exp Med Biol 2025: 1474; 105-118.
Bagherpour R, Bagherpour G, and Mohammadi P. Application of Artificial Intelligence in Tissue Engineering. Tissue Eng Part B Rev 2025: 31; 31-43.
Bardhan M, Muneer MA, Khare A, Minesh Shah R, Kaur A, Vasipalli SS, Suresh V, Podder V, Ahluwalia M, Odia Y, et al. Advances in stem cell-based therapeutic transfers for glioblastoma treatment. Expert Rev Neurother 2025: 25; 699-715.
Bentaleb M, Abdulrahman M, and Ribeiro MAF, Jr. Nanomedicine and Its Role in Surgical Wound Infections: A Practical Approach. Bioengineering (Basel) 2025: 12.
Bharti SK, V SM, Venkateswarlu M, Niveditha M, Sharma S, and Bansal D. Efficacy of stem cell therapy for avascular necrosis of the femoral head: A systematic review and Meta-analysis. Bone 2025: 200; 117590.
Calafiore R. Developing Stem Cell Therapy for Type 1 Diabetes Mellitus. Diabetes Metab Res Rev 2025: 41; e70079.
Canchi Sistla H, Talluri S, Rajagopal T, Venkatabalasubramanian S, and Rao Dunna N. Genomic instability in ovarian cancer: Through the lens of single nucleotide polymorphisms. Clin Chim Acta 2025: 565; 119992.
Cao M, Liu Y, Sun Y, Han R, and Jiang H. Current advances in human-induced pluripotent stem cell-based models and therapeutic approaches for congenital heart disease. Mol Cell Biochem 2025: 480; 159-172.
Chang L, Liu J, Zhu J, Guo S, Wang Y, Zhou Z, and Wei X. Advancing precision medicine: the transformative role of artificial intelligence in immunogenomics, radiomics, and pathomics for biomarker discovery and immunotherapy optimization. Cancer Biol Med 2025: 22; 33-47.
Chen K, Yang H, and Cai R. Microfluidics for Nanomedicine Delivery. ACS Biomater Sci Eng 2025: 11; 774-783.
Chen S, Yoo JJ, and Wang M. The application of tissue engineering strategies for uterine regeneration. Mater Today Bio 2025: 31; 101594.
Chen YL, Xiao JR, Zhu XX, Ni ZM, Huang S, Zhang ZR, Zhang Q, Yin H, Zhang Y, and Cai L. A review of recent advances in tissue engineering scaffolds for meniscus repair. Injury 2025: 56; 112283.
Choudhery MS, Arif T, and Mahmood R. Applications of artificial intelligence in stem cell therapy. World J Stem Cells 2025: 17; 106086.
Davlet M, Smyrnova K, and Pogrebnjak A. Advanced biomaterials in tissue engineering: A critical review of nanocomposites based on bacterial cellulose, MXenes, hydroxyapatite, and metal particles for regenerative medicine. Adv Colloid Interface Sci 2025: 345; 103634.
De Sario Velasquez GD, Tanas Y, Taraballi F, Herzog T, and Spiegel A. State of Research on Tissue Engineering with 3D Printing for Breast Reconstruction. J Clin Med 2025: 14.
Dipankar P, Salazar D, Dennard E, Mohiyuddin S, and Nguyen QC. Artificial intelligence based advancements in nanomedicine for brain disorder management: an updated narrative review. Front Med (Lausanne) 2025: 12; 1599340.
Dong N, Ali-Khiavi P, Ghavamikia N, Pakmehr S, Sotoudegan F, Hjazi A, Gargari MK, Gargari HK, Behnamrad P, Rajabi M, et al. Nanomedicine in the treatment of Alzheimer's disease: bypassing the blood-brain barrier with cutting-edge nanotechnology. Neurol Sci 2025: 46; 1489-1507.
Dubey AK, Brijesh H, Zhang Y, Shen B, Calina D, Sharifi-Rad J, and Singla RK. Tissue engineering with bionanomaterials: A new frontier. Phytomedicine 2025: 149; 157380.
Emran TB, Al Amin M, Rab SO, Jahnavi P, Vodeti R, Gupta JK, Arjun U, Umamaheswari TN, Balaji P, Dayalan G, et al. Advances in nanomedicine strategies for modulating the tumor microenvironment: Recent progress and clinical perspectives. 3 Biotech 2026: 16; 36.
Feng Z, Yang Y, Liu XZ, Sun HJ, Wen BY, Chen Z, and Wei B. Application of cell therapy in rheumatoid Arthritis: Focusing on the immunomodulatory strategies of Mesenchymal stem cells. Int Immunopharmacol 2025: 147; 114017.
Forgham H, Chang Y, Wang Y, Zhu J, Liu L, Biggs H, Kakinen A, Jiang Y, You X, Thurecht KJ, et al. The evolution of nanomedicine: The rise of next-generation nanomaterials in cancer nanomedicine. Sci Adv 2025: 11; eadx1576.
Gao J, Zhou X, Jiang N, Zhang Y, Han J, Jia T, Jiang Y, Ma X, and Shen H. Meta-analysis of mesenchymal stem cell therapy for intrauterine adhesions: a comprehensive consideration of efficacy and safety. Front Bioeng Biotechnol 2025: 13; 1619778.
Gao Y, Yuan Y, Wang K, Wang Y, Gao T, Yang Y, Ma LS, Li R, Wang G, and Liu X. Current progress and open challenges for applying artificial intelligence across the in vitro fertilization cycle. Patterns (N Y) 2025: 6; 101347.
Ghahremani-Nasab M, Babaie S, Bazdar S, Paiva-Santos AC, Del Bakhshayesh MR, Akbari-Gharalari N, Fathi-Karkan S, Ghasemi D, and Del Bakhshayesh AR. Infertility treatment using polysaccharides-based hydrogels: new strategies in tissue engineering and regenerative medicine. J Nanobiotechnology 2025: 23; 162.
Guo K, Li S, Wu X, and Xiong H. Nanomedicine in the Diagnosis and Treatment of Pancreatic Cancer. Pharmaceutics 2025: 17.
Guo Q and Hua Y. Stem Cell Therapy in Ischemic Heart Failure. Am J Cardiovasc Drugs 2025: 25; 601-632.
Held M, Castillo-Madeen H, Vigh-Conrad KA, Aston KI, and Conrad DF. Genetic and genomic insights into male reproductive tract development. Fertil Steril 2025: 123; 970-979.
Hetta HF, Elsaghir A, Sijercic VC, Ahmed AK, Gad SA, Zeleke MS, Alanazi FE, and Ramadan YN. Clinical Progress in Mesenchymal Stem Cell Therapy: A Focus on Rheumatic Diseases. Immun Inflamm Dis 2025: 13; e70189.
Horta F, Sakkas D, Ledger W, Goldys EM, and Gilchrist RB. Could metabolic imaging and artificial intelligence provide a novel path to non-invasive aneuploidy assessments? A certain clinical need. Reprod Fertil Dev 2025: 37.
Jamalinia M and Weiskirchen R. Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment. Ann Transl Med 2025: 13; 18.
Joshi S and Sheth S. Artificial Intelligence (AI) in Pharmaceutical Formulation and Dosage Calculations. Pharmaceutics 2025: 17.
Kakkar P, Gupta S, Paschopoulou KI, Paschopoulos I, Paschopoulos I, Siafaka V, and Tsonis O. The integration of artificial intelligence in assisted reproduction: a comprehensive review. Front Reprod Health 2025: 7; 1520919.
Khosravi P, Fuchs TJ, and Ho DJ. Artificial Intelligence-Driven Cancer Diagnostics: Enhancing Radiology and Pathology through Reproducibility, Explainability, and Multimodality. Cancer Res 2025: 85; 2356-2367.
Koldenhof J, Verhaar MC, Masereeuw R, Slaats GG, and van Genderen AM. How a kidney microenvironment atlas can advance kidney tissue engineering. Trends Biotechnol 2025.
Kwon J, Park Y, and Ha T. Unveiling the invisible genomic dynamics. Exp Mol Med 2025: 57; 1400-1408.
Le NT, Dunleavy MW, Zhou W, Bhatia SS, Kumar RD, Woo ST, Ramirez-Pulido G, Ramakrishnan KS, and El-Hashash AH. Stem Cell Therapy for Myocardial Infarction Recovery: Advances, Challenges, and Future Directions. Biomedicines 2025: 13.
Lekhavadhani S, Babu S, Shanmugavadivu A, and Selvamurugan N. Recent progress in alginate-based nanocomposites for bone tissue engineering applications. Colloids Surf B Biointerfaces 2025: 250; 114570.
Li S, Meng X, Zhong Z, and Li C. Advances in 3D bioprinting of functional biomaterials for neural tissue engineering. Tissue Cell 2025: 96; 103024.
Liu L, Behera TR, Wang QJ, and Shen QQ. Advances in mesenchymal stem cell therapy for lupus nephritis. World J Stem Cells 2025: 17; 104930.
Liu X, Wang X, Wu X, Zhan S, Yang Y, and Jiang C. Airway basal stem cell therapy for lung diseases: an emerging regenerative medicine strategy. Stem Cell Res Ther 2025: 16; 29.
Mali SS, Thorat DS, Singh AK, Patil PR, Patil SS, Kundale A, Ushir YV, Bhagwat DA, Shafi S, and Singh S. Unrevealing the potential of fibrous biomaterials in cartilage tissue engineering: a review. Z Naturforsch C J Biosci 2025.
Mokhtari YG, Varnava I, Kyrgiannis K, Ampatsidou V, and Giakoumettis D. Stem cell therapy for Parkinson's disease: A new hope for neural regeneration. World J Biol Chem 2025: 16; 106850.
Nafar H, Mahdavi Sharif P, and Rezaei N. Advances in nanomedicine-based retinal drug delivery: mechanisms and translational applications. J Nanobiotechnology 2025.
Nematpour N, Abdi F, Ahmadifard Z, Amini N, Taleb M, and Ghanbari H. Nanomedicine-based approaches to protect cardiac tissue necrosis from ischemic events. Int J Pharm 2025: 690; 126226.
Olawade DB, Teke J, Adeleye KK, Weerasinghe K, Maidoki M, and Clement David-Olawade A. Artificial intelligence in in-vitro fertilization (IVF): A new era of precision and personalization in fertility treatments. J Gynecol Obstet Hum Reprod 2025: 54; 102903.
Orovou E, Tzimourta KD, Tzitiridou-Chatzopoulou M, Kakatosi A, and Sarantaki A. Artificial Intelligence in Assisted Reproductive Technology: A New Era in Fertility Treatment. Cureus 2025: 17; e81568.
Qaderi K, Sharifipour F, Dabir M, Shams R, and Behmanesh A. Artificial intelligence (AI) approaches to male infertility in IVF: a mapping review. Eur J Med Res 2025: 30; 246.
Qayyum H, Ishaq Z, Ali A, Kayani MUR, and Huang L. Genome-resolved metagenomics from short-read sequencing data in the era of artificial intelligence. Funct Integr Genomics 2025: 25; 124.
Ramavat A, Antil P, Kaushik S, Kataria B, and Pandey RP. Nanomedicine for Cancer and Autoimmune Immunotherapy. Int J Mol Sci 2025: 26.
Ramezani Farani M, Mirzaee D, Hassanpour M, Nayebizadeh B, Mohades F, Azarian M, Chamani S, Simchi A, and Huh YS. Advancements in Nanomedicine for Allergic Diseases: Diagnosis, Toxicity, and Therapeutic Strategies. Chem Res Toxicol 2025: 38; 1818-1843.
Saadh MJ, Ahmed HH, Kareem RA, Ballal S, Sharma S, Guntaj J, Siva Prasad GV, Taher WM, Alwan M, Jawad MJ, et al. Stem Cell Therapy: A New Approach and Effective Treatment for Psoriasis. Dermatol Pract Concept 2025: 15.
Srivastava R. Advancing precision oncology with AI-powered genomic analysis. Front Pharmacol 2025: 16; 1591696.
Tan F, Du Z, Zhong J, Wu Y, Mou J, Zhao F, Liu Y, Chen J, Liang Z, Zhou Y, et al. Application of Nanomedicine in Tumor Targeting Inflammatory Pathway. Curr Med Chem 2025: 32; 2291-2329.
Tang J, Li D, Wang R, Li S, Xing Y, and Yu F. Engineered extracellular vesicles: an emerging nanomedicine therapeutic platform. Chem Commun (Camb) 2025: 61; 4123-4146.
Troiani Z, Chipman DE, Ryan TJ, Haider MN, Kowalski D, Hasanspahic B, Scott MM, Vallee EK, and Lucasti C. Efficacy of Mesenchymal and Embryonic Stem Cell Therapy for the Treatment of Spinal Cord Injury: A Systematic Review and Meta-Analysis of Human Studies. Global Spine J 2025: 15; 3969-3981.
Vieira Mourato B and Haubold B. Fast detection of unique genomic regions. Comput Struct Biotechnol J 2025: 27; 843-850.
Wang L, Fatemi M, and Alizad A. Artificial intelligence in fetal brain imaging: Advancements, challenges, and multimodal approaches for biometric and structural analysis. Comput Biol Med 2025: 192; 110312.
Wang M, Ran Y, Liang J, Li F, Li N, Ding Z, Xi J, Su W, Ye L, and Liu Z. Biomaterials-driven stem cell therapy for tissue repair and functional rehabilitation after ischemic stroke. Bioeng Transl Med 2025: 10; e70060.
Wen X, Hao Z, Yin H, Min J, Wang X, Sun S, and Ruan G. Engineered Extracellular Vesicles as a New Class of Nanomedicine. Chem Bio Eng 2025: 2; 3-22.
Wilting J, Becker J, and Tsikolia N. Embryonic mesenchyme, mesenchymal tumors and mesenchymal stem cells: need for clarification of cell types and standardization of biomedical terminology. Cell Mol Life Sci 2025: 82; 401.
Xie Y, Zhang L, Sun W, Zhu Y, Zhang Z, Chen L, Xie M, and Zhang L. Artificial Intelligence in Diagnosis of Heart Failure. J Am Heart Assoc 2025: 14; e039511.
Ye D, Liu H, Dai E, Fan J, and Wu L. Recent advances in nanomedicine design strategies for targeting subcellular structures. iScience 2025: 28; 111597.
Zack M, Stupichev DN, Moore AJ, Slobodchikov ID, Sokolov DG, Trifonov IF, and Gobbs A. Artificial Intelligence and Multi-Omics in Pharmacogenomics: A New Era of Precision Medicine. Mayo Clin Proc Digit Health 2025: 3; 100246.
Zuo DB, Wang CH, Sang M, Sun XD, Chen GP, and Ji KK. Stem cell therapy for diabetes: Advances, prospects, and challenges. World J Diabetes 2025: 16; 107344.
此全文未授權公開